KR101179110B1 - 이미다졸-5-카복실산 유도체 및 그 제조방법 및 그 용도 - Google Patents

이미다졸-5-카복실산 유도체 및 그 제조방법 및 그 용도 Download PDF

Info

Publication number
KR101179110B1
KR101179110B1 KR1020087022811A KR20087022811A KR101179110B1 KR 101179110 B1 KR101179110 B1 KR 101179110B1 KR 1020087022811 A KR1020087022811 A KR 1020087022811A KR 20087022811 A KR20087022811 A KR 20087022811A KR 101179110 B1 KR101179110 B1 KR 101179110B1
Authority
KR
South Korea
Prior art keywords
methyl
imidazole
carboxylic acid
butyl
tetrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087022811A
Other languages
English (en)
Korean (ko)
Other versions
KR20080096707A (ko
Inventor
지안휘 구오
동 안
Original Assignee
상하이 알리스트 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 알리스트 파마슈티컬즈 인코포레이티드 filed Critical 상하이 알리스트 파마슈티컬즈 인코포레이티드
Publication of KR20080096707A publication Critical patent/KR20080096707A/ko
Application granted granted Critical
Publication of KR101179110B1 publication Critical patent/KR101179110B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020087022811A 2006-02-20 2006-07-31 이미다졸-5-카복실산 유도체 및 그 제조방법 및 그 용도 Expired - Fee Related KR101179110B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2006100239910A CN101024643A (zh) 2006-02-20 2006-02-20 咪唑－5－羧酸类衍生物、制备方法及其应用
CN200610023991.0 2006-02-20
PCT/CN2006/001914 WO2007095789A1 (en) 2006-02-20 2006-07-31 Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof

Publications (2)

Publication Number Publication Date
KR20080096707A KR20080096707A (ko) 2008-10-31
KR101179110B1 true KR101179110B1 (ko) 2012-09-07

Family

ID=38436915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022811A Expired - Fee Related KR101179110B1 (ko) 2006-02-20 2006-07-31 이미다졸-5-카복실산 유도체 및 그 제조방법 및 그 용도

Country Status (12)

Country Link
US (2) USRE44873E1 (enExample)
EP (1) EP1988090B1 (enExample)
JP (1) JP5250760B2 (enExample)
KR (1) KR101179110B1 (enExample)
CN (2) CN101024643A (enExample)
AU (1) AU2006338796B2 (enExample)
CA (1) CA2643005C (enExample)
DK (1) DK1988090T3 (enExample)
ES (1) ES2424154T3 (enExample)
PL (1) PL1988090T3 (enExample)
PT (1) PT1988090E (enExample)
WO (1) WO2007095789A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
ATE525371T1 (de) * 2006-12-06 2011-10-15 Shanghai Allist Pharmaceutical Inc Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) * 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
US8207208B2 (en) * 2008-05-15 2012-06-26 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
JP5575783B2 (ja) * 2008-12-12 2014-08-20 ファーマコステック カンパニー リミテッド トリフェニルメタン保護基の除去方法
KR101213467B1 (ko) * 2010-04-30 2012-12-20 진양제약주식회사 로자탄 대사체 이엑스피-3174 이수화물의 신규한 제조 방법
CN103012377A (zh) * 2011-09-27 2013-04-03 江苏艾力斯生物医药有限公司 一种咪唑-5-羧酸酯的重结晶方法
CN102558064B (zh) * 2012-01-29 2014-04-16 安润医药科技（苏州）有限公司 抗高血压化合物及其制备方法和应用，以及其在药学上可接受的盐
CN104610232B (zh) * 2013-11-01 2019-09-20 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物
CN103965171A (zh) * 2014-04-30 2014-08-06 上海艾力斯医药科技有限公司 一种阿利沙坦酯的制备方法
CN106188012B (zh) * 2014-06-20 2018-11-30 深圳信立泰药业股份有限公司 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物
CN105218527B (zh) * 2015-10-10 2018-04-24 江苏宝众宝达药业有限公司 一种exp-3174的制备方法
EP3406610B1 (en) 2016-01-20 2025-03-05 Shenzhen Salubris Pharmaceuticals Co., Ltd Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
CN119371408B (zh) * 2024-12-27 2025-04-22 安徽艾立德制药有限公司 一种无定形的阿利沙坦酯及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011646A2 (en) 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
AT398202B (de) * 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
ATE199548T1 (de) * 1992-06-02 2001-03-15 Sankyo Co 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung
JPH083162A (ja) * 1994-04-19 1996-01-09 Tanabe Seiyaku Co Ltd イミダゾピリジン誘導体及びその製法
CZ297975B6 (cs) * 1995-06-07 2007-05-09 G. D. Searle & Co. Farmaceutická kombinace antagonisty receptoru proangiotensin II a epoxymexrenonu pro lécení kardiovaskulárních poruch
EP1668008A4 (en) * 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
ES2334386T3 (es) 2005-04-22 2010-03-09 Daiichi Sankyo Company, Limited Producto farmaceutico para la prevencion o el tratamiento de una enfermedad metabolica osea.
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
ATE525371T1 (de) 2006-12-06 2011-10-15 Shanghai Allist Pharmaceutical Inc Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011646A2 (en) 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
WO2007095789A1 (en) 2007-08-30
AU2006338796A1 (en) 2007-08-30
US20090036505A1 (en) 2009-02-05
JP2009527509A (ja) 2009-07-30
US7858651B2 (en) 2010-12-28
CN101031562A (zh) 2007-09-05
EP1988090A4 (en) 2010-06-30
CA2643005C (en) 2012-05-15
DK1988090T3 (da) 2013-08-05
EP1988090B1 (en) 2013-05-01
AU2006338796B2 (en) 2011-05-12
EP1988090A1 (en) 2008-11-05
USRE44873E1 (en) 2014-04-29
CA2643005A1 (en) 2007-08-30
PL1988090T3 (pl) 2013-10-31
JP5250760B2 (ja) 2013-07-31
PT1988090E (pt) 2013-08-05
ES2424154T3 (es) 2013-09-27
KR20080096707A (ko) 2008-10-31
CN100506818C (zh) 2009-07-01
CN101024643A (zh) 2007-08-29

Similar Documents

Publication Publication Date Title
KR101179110B1 (ko) 이미다졸-5-카복실산 유도체 및 그 제조방법 및 그 용도
EP0459136B1 (en) Benzimidazole derivatives, their production and use
HK1000803B (en) Benzimidazole derivatives, their production and use
CN111943932B (zh) 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
EP0539509B1 (en) 4-alkylimidazole derivatives
US7943648B2 (en) Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
JP2009527509A5 (enExample)
EP3447054B1 (en) Compound and preparation method therefor, composition and application thereof
CN113620930B (zh) 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用
CN101798300B (zh) N-苯基吲哚甲基取代的双苯并咪唑衍生物及其降压等应用
KR100191898B1 (ko) 벤조푸란계 치환기를 갖는 피리딜 이미다졸 유도체, 그의 제조방법 및 그를 함유하는 혈압강하제
JP2794637B2 (ja) イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
KR20100110438A (ko) 올메살탄의 신규한 에스테르 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
EP1355899A1 (en) Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
AU2002222407A1 (en) Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
HK1013995B (en) Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20120725

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2008 7022811

Appeal request date: 20110809

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2011101005511

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150821

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160819

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240829

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240829